{"id":"https://openalex.org/W7029767902","doi":null,"title":"Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I)","display_name":"Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I)","publication_year":2018,"publication_date":"2018-01-01","ids":{"openalex":"https://openalex.org/W7029767902"},"language":"en","primary_location":{"id":"pmh:oai:research-repository.griffith.edu.au:10072/403218","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10072/403218","pdf_url":null,"source":{"id":"https://openalex.org/S7407064376","display_name":"Griffith Research Online","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Conference output"},"volume":null,"type":"conference-paper","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/10072/403218","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Broadley, S","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Broadley, S","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038373894","display_name":"Heinz Wiendl","orcid":"https://orcid.org/0000-0003-4310-3432","observed_orcids":["https://orcid.org/0000-0003-4310-3432","https://orcid.org/0000-0001-5509-1075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wiendl, H","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Fernandez, O","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fernandez, O","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Freedman, MS","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Freedman, MS","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Izquierdo, G","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Izquierdo, G","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lycke, J","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lycke, J","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083385630","display_name":"Carlo Pozzilli","orcid":"https://orcid.org/0000-0002-6360-4798","observed_orcids":["https://orcid.org/0000-0002-6360-4798"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pozzilli, C","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Sharrack, B","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharrack, B","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Singer, BA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Singer, BA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Steingo, B","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steingo, B","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025462803","display_name":"Patrick Vermersch","orcid":"https://orcid.org/0000-0003-0997-8817","observed_orcids":["https://orcid.org/0000-0003-0997-8817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vermersch, P","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Wray, S","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wray, S","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Wijmeersch, BV","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wijmeersch, BV","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Ziemssen, T","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ziemssen, T","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"et al.","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"et al.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alemtuzumab","display_name":"alemtuzumab","score":1.0},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9729999899864197},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.6309999823570251},{"id":"https://openalex.org/keywords/annualized-relapse-rate","display_name":"annualized relapse rate","score":0.8510000109672546},{"id":"https://openalex.org/keywords/confirmed-disability-worsening","display_name":"confirmed disability worsening","score":0.8939999938011169},{"id":"https://openalex.org/keywords/brain-atrophy","display_name":"brain atrophy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/mri-disease-activity","display_name":"MRI activity","score":0.9449999928474426},{"id":"https://openalex.org/keywords/interferon-beta-1a","display_name":"interferon beta-1a","score":0.7570000290870667},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4189999997615814}],"concepts":[{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.9251999855041504},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9013000130653381},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4708999991416931},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35350000858306885},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.353300005197525},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.31209999322891235},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.27799999713897705},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.27549999952316284},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.2703000009059906},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.23960000276565552}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:research-repository.griffith.edu.au:10072/403218","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10072/403218","pdf_url":null,"source":{"id":"https://openalex.org/S7407064376","display_name":"Griffith Research Online","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Conference output"}],"best_oa_location":{"id":"pmh:oai:research-repository.griffith.edu.au:10072/403218","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10072/403218","pdf_url":null,"source":{"id":"https://openalex.org/S7407064376","display_name":"Griffith Research Online","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Conference output"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2810495986","https://openalex.org/W2800702435","https://openalex.org/W2771532908","https://openalex.org/W4389446327","https://openalex.org/W2983891338","https://openalex.org/W2550355049","https://openalex.org/W2626225244","https://openalex.org/W4389446056","https://openalex.org/W6925424593","https://openalex.org/W2746924405"],"abstract_inverted_index":{"Background:":[0],"In":[1],"CARE-MS":[2,51],"I":[3,52],"(NCT00530348),":[4],"2":[5,23,126,240],"courses":[6,241],"of":[7,40,95,148,183,197,227],"alemtuzumab":[8,45,202,235],"(baseline:":[9],"5":[10],"days;":[11],"12":[12],"months":[13],"later:":[14],"3":[15],"days)":[16],"improved":[17],"outcomes":[18,208],"vs":[19],"SC":[20],"IFNB-1a":[21],"over":[22,47,131],"years":[24,49],"in":[25,34,38,50,108,116,121],"treatment-naive":[26],"RRMS":[27],"patients.":[28],"Durable":[29],"6-year":[30],"efficacy":[31,46],"was":[32],"demonstrated":[33],"an":[35],"extension":[36],"(NCT00930553)":[37],"absence":[39],"continuous":[41],"treatment.":[42],"Objective:":[43],"Evaluate":[44],"6":[48],"patients":[53,97,184,198],"who":[54,199],"relapsed":[55,98,200],"between":[56,99,201],"Courses":[57,100,203],"1":[58,101,118,204,223],"and":[59,81,102,128,144,151,160,205,232],"2.":[60,103],"Methods:":[61],"Assessments:":[62],"annualised":[63],"relapse":[64,220],"rate":[65],"(ARR);":[66],"6-month":[67,72],"confirmed":[68,73],"disability":[69,74],"worsening":[70],"(CDW);":[71],"improvement":[75],"(CDI);":[76],"MRI":[77,156],"disease":[78,157],"activity":[79,158],"(Gd+":[80],"new/enlarging":[82,152],"T2":[83,153],"lesions);":[84],"new":[85,161],"T1":[86,162],"hypointense":[87,163],"lesions;":[88],"brain":[89],"volume":[90],"loss":[91],"(BVL).":[92],"Results:":[93],"15%":[94,196],"alemtuzumab-treated":[96],"Of":[104],"these,":[105],"93%":[106],"enrolled":[107],"extension;":[109],"87%":[110],"remained":[111,129],"through":[112],"Year":[113,117,136],"6.":[114],"ARR":[115],"(1.3)":[119],"declined":[120,170],"the":[122,238],"year":[123],"after":[124,221],"Course":[125,180,222],"(0.3)":[127],"low":[130],"Years":[132],"3\u20136":[133],"(0.3\u20130.5).":[134],"At":[135],"6,":[137],"60%":[138],"were":[139,146,209],"CDW-free,":[140],"24%":[141],"achieved":[142],"CDI,":[143],"most":[145],"free":[147],"Gd+":[149],"(84%)":[150],"(71%)":[154],"lesions,":[155],"(69%),":[159],"lesions":[164],"(90%).":[165],"Median":[166],"percent":[167],"yearly":[168],"BVL":[169],"(Years":[171],"1\u20136:":[172],"\u20130.67%,":[173],"\u20130.17%,":[174],"\u20130.20%,":[175],"\u20130.11%,":[176],"\u20130.21%,":[177],"\u20130.24%).":[178],"After":[179],"2,":[181,206],"48%":[182],"received":[185],"no":[186],"additional":[187],"treatment":[188,230],"(alemtuzumab":[189],"or":[190],"other":[191],"disease-modifying":[192],"therapy).":[193],"Conclusions:":[194],"Among":[195],"long-term":[207],"favourable,":[210],"with":[211],"nearly":[212],"one-quarter":[213],"achieving":[214],"CDI.":[215],"These":[216],"data":[217],"indicate":[218],"that":[219],"is":[224],"not":[225],"indicative":[226],"subsequent":[228],"limited":[229],"response":[231],"support":[233],"administering":[234],"according":[236],"to":[237,242],"approved":[239],"achieve":[243],"optimal":[244],"clinical":[245],"benefit.":[246]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-10-10T00:00:00"}